Ashraf Fawzy1, Nirupama Putcha1, Carrie P Aaron2, Russell P Bowler3, Alejandro P Comellas4, Christopher B Cooper5, Mark T Dransfield6, MeiLan K Han7, Eric A Hoffman8, Richard E Kanner9, Jerry A Krishnan10, Wassim W Labaki7, Robert Paine9, Laura M Paulin11, Stephen P Peters12, Robert Wise1, R Graham Barr2, Nadia N Hansel13. 1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD. 2. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY. 3. Department of Medicine, National Jewish Medical and Research Center, Denver, CO. 4. Division of Pulmonary, Critical Care, and Occupational Medicine, University of Iowa College of Medicine, Iowa City, IA. 5. Department of Medicine and Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, CA. 6. Lung Health Center and Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL. 7. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI. 8. Department of Radiology, University of Iowa, Iowa City, IA. 9. Division of Respiratory, Critical Care and Occupational Medicine, University of Utah Health Sciences Center, Salt Lake City, UT. 10. Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL. 11. Department of Medicine, Dartmouth-Hitchcock Medical Center /Geisel School of Medicine at Dartmouth, Lebanon, NH. 12. Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest University, Winston-Salem, NC. 13. Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: nhansel1@jhmi.edu.
Abstract
BACKGROUND: Aspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. However, the effect of aspirin on COPD morbidity is unknown. METHODS: Self-reported daily aspirin use was obtained at baseline from SPIROMICS participants with COPD (FEV1/FVC < 70%). Acute exacerbations of COPD (AECOPD) were prospectively ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring ED visit or hospitalization). Aspirin users were matched one-to-one with nonusers, based on propensity score. The association of aspirin use with total, moderate, and severe AECOPD was investigated using zero-inflated negative binomial models. Linear or logistic regression was used to investigate the association with baseline respiratory symptoms, quality of life, and exercise tolerance. RESULTS: Among 1,698 participants, 45% reported daily aspirin use at baseline. Propensity score matching resulted in 503 participant pairs. Aspirin users had a lower incidence rate of total AECOPD (adjusted incidence rate ratio [IRR], 0.78; 95% CI, 0.65-0.94), with similar effect for moderate but not severe AECOPD (IRR, 0.86; 95% CI, 0.63-1.18). Aspirin use was associated with lower total St. George's Respiratory Questionnaire score (β, -2.2; 95% CI, -4.1 to -0.4), reduced odds of moderate-severe dyspnea (modified Medical Research Council questionnaire score ≥ 2; adjusted odds ratio, 0.69; 95% CI, 0.51-0.93), and COPD Assessment Test score (β, -1.1; 95% CI, -1.9 to -0.2) but not 6-min walk distance (β, 0.7 m; 95% CI, -14.3 to 15.6). CONCLUSIONS: Daily aspirin use is associated with reduced rate of COPD exacerbations, less dyspnea, and better quality of life. Randomized clinical trials of aspirin use in COPD are warranted to account for unmeasured and residual confounding. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www.clinicaltrials.gov.
BACKGROUND:Aspirin use in COPD has been associated with reduced all-cause mortality in meta-regression analysis with few equivocal studies. However, the effect of aspirin on COPD morbidity is unknown. METHODS: Self-reported daily aspirin use was obtained at baseline from SPIROMICS participants with COPD (FEV1/FVC < 70%). Acute exacerbations of COPD (AECOPD) were prospectively ascertained through quarterly structured telephone questionnaires up to 3 years and categorized as moderate (symptoms treated with antibiotics or oral corticosteroids) or severe (requiring ED visit or hospitalization). Aspirin users were matched one-to-one with nonusers, based on propensity score. The association of aspirin use with total, moderate, and severe AECOPD was investigated using zero-inflated negative binomial models. Linear or logistic regression was used to investigate the association with baseline respiratory symptoms, quality of life, and exercise tolerance. RESULTS: Among 1,698 participants, 45% reported daily aspirin use at baseline. Propensity score matching resulted in 503 participant pairs. Aspirin users had a lower incidence rate of total AECOPD (adjusted incidence rate ratio [IRR], 0.78; 95% CI, 0.65-0.94), with similar effect for moderate but not severe AECOPD (IRR, 0.86; 95% CI, 0.63-1.18). Aspirin use was associated with lower total St. George's Respiratory Questionnaire score (β, -2.2; 95% CI, -4.1 to -0.4), reduced odds of moderate-severe dyspnea (modified Medical Research Council questionnaire score ≥ 2; adjusted odds ratio, 0.69; 95% CI, 0.51-0.93), and COPD Assessment Test score (β, -1.1; 95% CI, -1.9 to -0.2) but not 6-min walk distance (β, 0.7 m; 95% CI, -14.3 to 15.6). CONCLUSIONS: Daily aspirin use is associated with reduced rate of COPD exacerbations, less dyspnea, and better quality of life. Randomized clinical trials of aspirin use in COPD are warranted to account for unmeasured and residual confounding. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www.clinicaltrials.gov.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: G Davì; S Basili; M Vieri; F Cipollone; S Santarone; C Alessandri; P Gazzaniga; C Cordova; F Violi Journal: Am J Respir Crit Care Med Date: 1997-12 Impact factor: 21.405
Authors: Samantha S C Kon; Jane L Canavan; Sarah E Jones; Claire M Nolan; Amy L Clark; Mandy J Dickson; Brigitte M Haselden; Michael I Polkey; William D-C Man Journal: Lancet Respir Med Date: 2014-02-04 Impact factor: 30.700
Authors: Alvar Agustí; Lisa D Edwards; Stephen I Rennard; William MacNee; Ruth Tal-Singer; Bruce E Miller; Jørgen Vestbo; David A Lomas; Peter M A Calverley; Emiel Wouters; Courtney Crim; Julie C Yates; Edwin K Silverman; Harvey O Coxson; Per Bakke; Ruth J Mayer; Bartolome Celli Journal: PLoS One Date: 2012-05-18 Impact factor: 3.240
Authors: Xu Gao; Brent Coull; Xihong Lin; Pantel Vokonas; Joel Schwartz; Andrea A Baccarelli Journal: Am J Respir Crit Care Med Date: 2020-02-01 Impact factor: 21.405
Authors: Robert M Burkes; Agathe S Ceppe; David J Couper; Alejandro P Comellas; J Michael Wells; Stephen P Peters; Gerard J Criner; Richard E Kanner; Robert Paine; Stephanie A Christenson; Christopher B Cooper; Igor Z Barjaktarevic; Jerry A Krishnan; Wassim W Labaki; MeiLan K Han; Jeffrey L Curtis; Nadia N Hansel; Robert A Wise; M Bradley Drummond Journal: Chronic Obstr Pulm Dis Date: 2020-10